SPDR S&P Midcap 400

Third Pillar Fund Increases Twilio Holdings, Directors and CFO Sell Shares

United Therapeutics CFO James Edmonds Sells $5.64M in Stock

United Therapeutics Announces Tyvaso Met Primary Endpoint in IPF Phase 3 Trial, Plans FDA Submission for New Indication

TD Cowen Analyst Thome Reaffirms Buy Rating on United Therapeutics with $675 Target

United Therapeutics announces Phase III trial success for ralinepag, plans FDA submission in late 2026

Fabrinet Reports FY2026 Q3 Results and Issues Cautious Q4 Guidance

United Therapeutics CFO James Edgemond Sells 10,000 Shares for $5.74 Million

nVent Announces Stock Repurchase Authorization

Twilio Receives Moderate Buy Rating with $193.65 Target Price, Executives Sell Shares

Combination Therapy Approved by FDA to Launch Pig-Derived UHeart Xenotransplant Clinical Trial

Valeo Financial Advisors Acquires $571k of Flex Ltd. Stock in Q4

Twilio Board Member Sells Company Shares

nVent Electric Executive Obtained Stock Options

Guggenheim Upgrades MasTec Rating to Buy

Flex Executives Sell Shares

Twilio Director Andrew Stafman Sells 675,000 A-Class Ordinary Shares

nVent Electric plc CTO Reduced Company Shares

Martha Claire Bennett exercises stock options and sells shares

First National Advisers LLC Reduces Holdings in MasTec, Inc.

James Edgemond Sells United Therapeutics Stock

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

GCL Global

MetaVia

Arcadia Biosciences

Silexion Therapeutics

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

MCOW

VTWV

SPMD

MIDE

VTWG

Brent Schutte, Northwestern Mutual CIO, joins 'Closing Bell Overtime' to discuss what's behind this week's market rally, the state of the U.S. economy, how AI advancements are moving markets, and more.

Pacer S&P MidCp 400 Qul FCF Arstcrts ETF

Vanguard Russell 2000 Value

Vanguard Russell 2000

ProShares Ultra Russell2000 ETF

Global X Russell 2000 ETF

iShares Core S&P Small Cap

SPDR Portfolio S&P 400 Mid Cap ETF

iShares Core S&P Mid Cap

ISHRS Russ 2000 Growth

Xtrackers S&P MidCap 400 ESG ETF

ProShares Russell 2000 High Income ETF

iShares Russell 2000

Vanguard Russell 2000 Growth

Direxion Small Cap Bull 3X

Pro Rsl 2000 Dvd Grw

Small to mid-caps will grow in valuation due to AI benefits: Northwestern Mutual's Brent Schutte

IVOO

As global markets recover post-U.S.-Iran ceasefire, small-cap stocks like S&P MidCap 400 and Russell 2000 gain traction. Investors are eyeing undervalued small caps with insider buying as indicators of potential value. Notable picks include Eastnine, MedCap, and MCAN Mortgage, each showing strong fundamentals and insider confidence despite some financial challenges. Eastnine reported a turnaround in performance, MedCap's revenue growth is promising, and MCAN Mortgage increased dividends, reflecting optimism. The article highlights 170 undervalued global small caps for investors to consider.

Simplywall

ISHRS S&P M-Cap 400/Barra Growth

VG Mid-Cap Val

NEOS Russell 2000 High Income ETF

ISHRS Russ 2000 Val

VG S&P M-Cap 400 Val

VG S-Cp Grw

Wtree Us M-Cp Fund

SPDR S&P 600 S-Cp Val

SPDR S&P 400 Mid Capgrow

Avantis U.S. Small Cap Value

VG S&P M-Cap 400

Global's Top 3 Undervalued Small Caps With Insider Buying To Consider

DTCR

DigitalOcean Holdings will join the S&P MidCap 400 on April 9, 2026, impacting its capital allocation and trading profile. This move may influence perceptions of growth and risk, particularly in relation to AI-driven growth and high debt levels. Analysts project $1.3 billion in revenue and $182 million in earnings by 2028, but caution exists around churn and pricing pressures. The stock's fair value is estimated at $59.58, indicating a potential downside. Investors are encouraged to consider both optimistic and cautious narratives regarding DigitalOcean's future.

Global X Data Center & Dgtl Infrs ETF

American Century Mid Cap Growth Impact ETF

Digitalocean

ISHRS S&P Glb It

Franklin Exponential Data ETF

Pacer Data & Infrastructure Real Estate ETF

iShares US Digital Infrastructure and Real Estate ETF

Global X Cloud Computing ETF

Proshares Big Data Refiners ETF

Does DigitalOcean (DOCN) Entering the S&P MidCap 400 Reframe Its Balance of Growth and Risk?

PSTG

The State Street SPDR S&P MIDCAP 400 ETF Trust (MDY) has experienced a significant outflow of approximately $230.2 million, marking a 1.0% decrease in shares outstanding week-over-week. Key components include TechnipFMC plc (FTI) up 0.4%, Woodward, Inc. (WWD) down 1.4%, and Everpure Inc (PSTG) down 3.1%. MDY's 52-week range is $458.82 to $662.65, with the last trade at $609.34. This outflow indicates a potential impact on the underlying holdings of the ETF.

nasdaq

Woodward

State Street

TechnipFMC

Everpure

MDY, FTI, WWD, PSTG: ETF Outflow Alert

COHR

The State Street SPDR S&P MIDCAP 400 ETF Trust (MDY) has seen a significant inflow of approximately $341.6 million, marking a 1.4% increase in outstanding units week-over-week. Key components include Coherent Corp (COHR) up 3.6%, TechnipFMC plc (FTI) down 0.4%, and Woodward, Inc. (WWD) up 1.7%. MDY's 52-week range is $458.82 to $662.65, with the last trade at $617.64. The ETF's performance is monitored weekly for notable inflows and outflows, impacting its underlying holdings.

Coherent Corp.

MDY, COHR, FTI, WWD: Large Inflows Detected at ETF

SOLS

Solstice Advanced Materials (NasdaqGS:SOLS) has been added to the S&P MidCap 400 during the March 2026 quarterly rebalancing, highlighting its growing significance in the AI supply chain. The stock, currently priced at $72.17, has seen a 46.4% year-to-date return, despite a recent 8.1% decline. This inclusion may influence trading volumes and ownership as index funds adjust their holdings. Analysts have set a target price of $83.83, indicating potential undervaluation. Investors are advised to monitor the company's performance and market positioning closely.

Solstice Advanced Materials

ISHRS S&P M-Cap 400/Barra Val

Solstice Joins S&P MidCap 400 As AI Supply Chain Valuation Story Grows

It's different than picking individual stocks. It's even a little bit different than owning more familiar index-based exchange-traded funds.

VG Mid-Cap

What investors should understand about mid-cap exposure through VO (or MDY)

Arrowhead Pharmaceuticals reported a significant profit surge in Q1 2026, with sales reaching $264.03 million and net income of $30.81 million, a stark contrast to the previous year's $2.5 million in sales. The company was also added to the S&P MidCap 400, indicating a shift in its financial profile. While this move may enhance liquidity and broaden the shareholder base, risks remain tied to clinical trials and partner-dependent revenue. Analysts have varying forecasts for Arrowhead's future revenue, with some projecting a decline, highlighting the uncertainty surrounding its investment narrative.

SPDR S&P Biotech

iShares US Pharma

ArrowHead Pharma

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Health Care Select Sector SPDR

VG Health

Is Arrowhead’s Profit Surge and S&P MidCap 400 Move Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?

The stock market is shifting focus from tech giants, known as the "Magnificent Seven," to small and mid-cap companies, which have outperformed with gains of 6-9% this year. The tech giants, facing valuation compression due to heavy investments in AI infrastructure, have seen their collective index drop over 3.2% year-to-date. While the broader market shows resilience with record high valuations, concerns grow over the sustainability of cash flow as companies invest heavily in future technologies. Valuation multiples for the tech leaders have compressed by 15-20%, reflecting investor caution regarding long-term returns.

Talkmarkets

From Superstars To The Bench: The Market Rediscovers Team Sports

JEPI

HIMS

Leading stocks such as $RSP, $MDY, $IYT, and $XLP have reached new highs, while Bitcoin ($BTC) is lagging behind. The video lesson reviews the recent rotation from 2025 to 2026 leading stocks, highlights potential scam stocks like $MSTR and $HIMS, and analyzes new long positions $CIEN and $VIK for the upcoming week.

- The lesson reviews the rotation from 2025 leading stocks to those for 2026, highlighting key indicators to avoid scam stocks like $MSTR and $HIMS.  
- It provides a quick analysis of current leading stocks and introduces two new long positions, $CIEN and $VIK, for next week.  
- The video focuses on strategic trading insights and stock performance trends.

iShares Core S&P 500

JPMorgan Equity Premium Inc ETF

SPDR S&P 500

Invesco S&P 500 Eq Wgt ETF

Hims & Hers Health

Leading Stocks Continue To Lead As $RSP $MDY $IYT $XLP Hit New Highs While Bitcoin $BTC Lags

SPDR S&P Midcap 400(MDY.US)

Small to mid-caps will grow in valuation due to AI benefits: Northwestern Mutual's Brent Schutte

Global's Top 3 Undervalued Small Caps With Insider Buying To Consider

Does DigitalOcean (DOCN) Entering the S&P MidCap 400 Reframe Its Balance of Growth and Risk?

MDY, FTI, WWD, PSTG: ETF Outflow Alert

MDY, COHR, FTI, WWD: Large Inflows Detected at ETF